[Featured Stock] Hanmi Pharm Soars on Expectations for COVID-19 Vaccine Contract Manufacturing
[Asia Economy Reporter Ji Yeon-jin] Hanmi Pharm is showing a sharp rise in the KOSPI market on the 22nd.
![[Image source=Yonhap News]](http://www.asiae.co.kr/news/img_view.htm?img=2021042311424194956_1619145762.jpg)
As of 2:38 PM on the same day, Hanmi Pharm is trading at 369,000 KRW, up 6.34% from the previous day.
The increase is attributed to the government's announcement of a roadmap starting in August for domestic pharmaceutical companies to produce overseas-approved COVID-19 vaccines, with Hanmi Pharm mentioned as a candidate.
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Kim Young-hoon, the Problem Solver Who Averted Samsung Electronics' General Strike... Breakthrough Achieved Through the Power of Dialogue
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
On the 15th, during a background briefing, the government announced that one domestic pharmaceutical company will produce one of the overseas-approved vaccines, naming GC Green Cross and Hanmi Pharm as strong candidates for overseas vaccine contract manufacturing (CMO).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
